How Racura’s New Blood Test Could Speed Up Heart Protection Data by Two Years

• Novel blood-based test developed to assess RC220’s cardioprotective effects
• Trial protocol amended to include doxorubicin monotherapy cycle for baseline data
• Regulatory approvals secured or pending across Australia, Hong Kong, and South Korea
• Blood test enables cardioprotection data collection two years earlier than planned